Alzheimer’s Disease Market in 8MM – Market Outlook, Unmet Needs, Market Assessment and Forecast (2023-2030)

Alzheimer’s Disease Market – Report Overview

Pacific Business Consulting’s “Alzheimer’s Disease Market in 8MM – Market Outlook, Unmet Needs, Market Assessment and Forecast (2023-2030)” report offers a comprehensive understanding of Alzheimer’s Disease, encompassing historical and projected market size data, along with market trends, market drivers, market barriers and unmet medical needs in the Eight Major Markets (8MM) of the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and China.

The Alzheimer’s Disease (AD), including Mild Cognitive Impairment (MCI), market size across the Eight Major Markets (8MM) was valued at US$3.7 billion in 2022 and is expected to achieve a double-digit Compound Annual Growth Rate (CAGR) growth during the forecast period from 2023 to 2030. The United States leads the Alzheimer’s Disease market, contributing to nearly 50% of the total sales, followed by Japan as the second-largest contributor. MCI represents a phase in the AD continuum characterized by a gradually progressive cognitive decline that may become clinically relevant. AD is a progressive neurodegenerative disease characterized by memory loss, cognitive impairment, and functional decline.

Pharmacological therapies for symptomatic treatment, such as acetylcholinesterase inhibitors (AChEIs) and the NMDA receptor antagonist memantine, have been available in the US for over a decade. The current Alzheimer’s Disease market consists of four main brands: Novartis’ Exelon (rivastigmine), Eisai’s Aricept (donepezil), Johnson & Johnson’s Razadyne (galantamine), and AbbVie/Lundbeck’s Namenda (memantine). These medications provide modest symptomatic benefits, but as they approach or reach the expiration of their patents, industry players are actively pursuing more effective medications to address the substantial unmet needs in this market.

The main drivers of the Alzheimer’s Disease market over the forecast period include the entry of disease-modifying therapies (DMTs), such as the passive immunotherapies Aduhelm (aducanumab), Leqembi (lecanemab), and donanema. The launch of novel symptomatic therapies like brexpiprazole and the increasing prevalence of Alzheimer’s Disease and MCI are expected to propel market growth in the coming years.

Key companies operating in the Alzheimer’s disease segment include Alzheon, Athira Pharma, Annovis Bio, Anavex Life Sciences, Eli Lilly, Eisai, BioVie, AB Science, Novo Nordisk, Cerecin, and KeifeRx.

Scope of Report

The report addresses critical subjects such as strategic competitor evaluation, market characterization, unmet needs, and the consequences of these elements for the Alzheimer’s Disease market. It also delves into the analysis of present and prospective market competition within the global Alzheimer’s Disease market.

Furthermore, the report offers an insightful examination of the primary industry drivers, constraints, and challenges. Each trend undergoes independent research to furnish qualitative analysis regarding its implications.

Reasons to Buy

• Develop your business strategies by gaining insights into the trends that shape and drive the Alzheimer’s Disease market across the 8MM (Eight Major Markets).
• Increase revenue by comprehending key trends, innovative products and technologies, market segments, and companies poised to influence the future of the 8MM Alzheimer’s Disease market.
• Craft effective sales and marketing strategies by thoroughly understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially robust product portfolios and devise strategic counter-strategies to gain a competitive advantage.
• Optimize your sales and marketing efforts by pinpointing market categories and segments that offer the greatest opportunities for consolidations, investments, and strategic partnerships.

Please note that detailed pipeline analysis can be provided along with the standard scope to assist you in developing and designing your in-licensing and out-licensing strategies. This includes a review of pipeline products and technologies, along with identifying companies with the most robust pipeline.

1. Executive Summary: Alzheimer’s Disease
   • Global Market Outlook: Alzheimer’s Disease
2. Competitive Intelligence Analysis: Alzheimer’s Disease
3. Therapeutic Sector SWOT
4. Technology Roadmap Analysis: Alzheimer’s Disease
5. Market Background
   • Drivers
   • Restraints
   • Opportunity
   • Key Market Trends
   • Key Unmet Needs
6. Disease Overview: Alzheimer’s Disease
   • Disease Etiology
   • Pathophysiology
   • Risk Factors
   • Treatment Algorithm
7. Alzheimer’s Disease: Key Marketed Products Profile – Major Approved Products
   • Product Profile
   • Regulatory Milestones
   • Safety and Efficacy
   • Clinical Development
8. Alzheimer’s Disease: Promising Pipeline Candidates – Major Products in Late Stage of Development
   • Product Description
   • Safety and Efficacy
   • Research and Development
9. Regulatory Landscape
10. Alzheimer’s Disease: Eight Major Market (8MM) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
11. S. Alzheimer’s Disease – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
12. K. Alzheimer’s Disease – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
13. Germany Alzheimer’s Disease – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
14. France Alzheimer’s Disease – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
15. Italy Alzheimer’s Disease – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
16. Spain Alzheimer’s Disease – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
17. Japan Alzheimer’s Disease – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
18. China Alzheimer’s Disease – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
19. Competitive Landscape
    • Company Overview
    • Product Portfolio
    • Key Financials
    • Sales Footprint

Note – All Major Company Profiles (Count up to 20) will be covered in the report

20. Assumptions and Acronyms Used
21. Research Methodology
    • Secondary Research
    • Primary Research
    • Data Triangulation
22. Geographic Scope
    • The U.S., The U.K., Germany, France, Italy, Spain, Japan, and China

Copyrights and Disclaimer